A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis

The PROteKT study tested the hypothesis that rosuvastatin can inhibit aminoglycoside-induced nephrotoxicity in children with Cystic Fibrosis (CF). This open label, parallel group, randomised controlled trial recruited children and young people aged 6 to 18 years with CF at 13 paediatric CF treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: McWilliam, Stephen J., Rosala-Hallas, Anna, Jones, Ashley P., Shaw, Victoria, Greenhalf, William, Jaki, Thomas, Smyth, Alan R., Smyth, Rosalind L., Pirmohamed, Munir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000680/
https://www.ncbi.nlm.nih.gov/pubmed/32020028
http://dx.doi.org/10.1038/s41598-020-58790-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000680/
https://www.ncbi.nlm.nih.gov/pubmed/32020028
http://dx.doi.org/10.1038/s41598-020-58790-1

Ejemplares similares